In a landmark moment for India’s private equity ecosystem, ChrysCapital has closed its tenth fund at $2.2 billion, marking the largest fund ever raised by an India-focused private equity firm.
The new Fund X represents a 60% jump from Fund IX, which had closed at $1.35 billion in 2022. The capital will be deployed across established businesses in consumer, healthcare, financial services, enterprise technology, and industrial sectors — areas where the firm has historically found strong value creation opportunities.
Since its inception in 1999, ChrysCapital has raised around $8.5 billion across ten private equity funds, a continuation vehicle, and a public markets fund. It has deployed over $5.5 billion across 110 portfolio companies and realised $7.8 billion from 80 successful exits, reportedly achieving a 3.0x return on investment.
Some of ChrysCapital’s notable investments include Intas Pharmaceuticals, Mankind Pharma, GeBBS Healthcare, Infogain, NSE, and Awfis, underlining its track record of identifying and scaling high-growth enterprises.
Fund X also marks a more diversified investor base, with over 30 new global limited partners (LPs), including pension funds, insurers, asset managers, and family offices from Japan, the Middle East, Southeast Asia, Europe, and the US. For the first time, ChrysCapital has also raised capital from Indian institutional investors and large family offices, reflecting rising domestic interest in the country’s private equity story.
The fund achieved its final close within six months of its first close — a testament to investor confidence in the firm’s track record and disciplined investment strategy.
Looking ahead, ChrysCapital plans to deploy Fund X over the next 3–4 years, with several transactions already in progress. The investment focus remains on businesses with robust governance, scalable models, and clear exit visibility, through both majority and minority stakes.
In India’s increasingly competitive private equity landscape, ChrysCapital continues to hold its ground among global heavyweights such as TPG, Bain Capital, KKR, Blackstone, Carlyle, Warburg Pincus, and Multiples — reaffirming its position as one of the country’s most trusted homegrown investment platforms.
-By Muskan Dengra
